NCT00145496View on ClinicalTrials.gov

Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771)

PHASE3CompletedINTERVENTIONAL
Enrollment

468

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

November 30, 2008

Study Completion Date

December 31, 2008

Conditions
Schizophrenia
Interventions
DRUG

Asenapine

5-10 mg sublingually twice daily for up to 26 weeks

DRUG

Olanzapine

5-20 mg by mouth once daily for up to 26 weeks

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT00145496 - Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771) | Biotech Hunter | Biotech Hunter